MENU

Can Tenax Therapeutics (TENX) Stock Reach $9.60?

a developer of novel therapeutic products

A.I.Advisor
published price charts
A.I.Advisor
Nov 22, 2026

Can Tenax Therapeutics (TENX) Stock Reach $9.60?

Tenax Therapeutics, Inc. (TENX) is a development-stage biopharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical need, including pulmonary hypertension and heart failure. After a failed Phase 3 trial sent shares down roughly 90% in a single session in August 2026, the stock now trades near $1.25, yet the surviving analyst price targets imply a far higher valuation. This article examines whether TENX can realistically reach $9.60 and what would have to happen for that move to occur.

Key Takeaways

  • The central target of $9.60 is the arithmetic mean of eight verified analyst price targets, which range from a low of $4 to a high of $35.
  • With the stock near $1.25, reaching $9.60 would require an upside of roughly 670% — a very large move for a micro-cap biotech.
  • The target reflects analyst views after severe post-trial target cuts; two additional firms (Guggenheim and William Blair) moved to Hold and withdrew price targets entirely.
  • The strongest supporting factors are a possible path in sicker PH-HFpEF (pulmonary hypertension with heart failure with preserved ejection fraction) subgroups, insider buying, and a strategic-alternatives review.
  • The biggest risks are the failed LEVEL Phase 3 trial, financing needs, and pending securities class-action lawsuits.
  • For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages.
  • Explore Trending AI Robots to see AI-driven trading strategies across thousands of stocks and ETFs.

Analyst Price Targets and Consensus View

The $9.60 central target is calculated from eight current, individually verified analyst price targets: $4 from Leerink Partners (October 2026), $4 from Canaccord Genuity (August 2026), $5 each from Chardan Capital, Evercore ISI, LifeSci Capital, and Roth MKM (August 2026, with Roth reiterating $5 in November 2026), $14 from Piper Sandler (September 2026), and $35 from Cantor Fitzgerald (September 2026). The unrounded mean of these eight targets is approximately $9.63, and the range is unusually wide at $4 to $35.

The dispersion tells its own story. Most firms clustered near $4 to $5 after the LEVEL trial failure, while Piper Sandler and Cantor Fitzgerald kept materially higher targets on the thesis that oral levosimendan retains value in more severely ill PH-HFpEF patients. Guggenheim and William Blair both downgraded to Hold and removed targets, so they are excluded from the mean. This is not a tightly aligned analyst consensus; it is a wide range reflecting genuine disagreement about the company's remaining clinical value.

Current Market Position and Path Toward the Target

As of the November 20, 2026 close, TENX traded at about $1.25, down from a 52-week high of $19.40. Reaching $9.60 would require an advance of roughly 670%, a very large move that would depend not on incremental progress but on a fundamental re-rating of the company's lead program. The market capitalization near $1.25 is only about $57 million, a reflection of post-trial skepticism about the pipeline's commercial prospects and the company's cash position.

The August 2026 announcement that TNX-103 (oral levosimendan) missed its primary endpoint — six-minute walk distance — and a key secondary symptom measure in the Phase 3 LEVEL trial triggered the collapse. Since then, attention has shifted to whether a subgroup of sicker patients, strategic options such as a sale or merger, and the company's imatinib-based program (TNX-201) can support value. Any path toward $9.60 would likely require new positive clinical data or a transformative corporate transaction.

What Could Support a Move Toward the Target

Several factors could underpin a recovery. Analysts at firms such as Roth MKM and Piper Sandler continue to cite a possible opportunity in severe PH-HFpEF, where subgroup analyses suggested stronger walk-distance and biomarker signals in sicker patients. The company has also announced it is evaluating strategic alternatives, including a sale or merger, with Roth Capital Partners as financial advisor — a process that, if concluded favorably, could unlock value beyond the current share price. Insider buying has been positive, with director Declan Doogan purchasing shares in September 2026, and a Phase 3-ready pipeline beyond TNX-103 provides optionality if trials are redesigned around responder populations.

What Could Prevent the Target From Being Reached

The obstacles are substantial. The LEVEL trial failure means the lead asset lacks validated pivotal efficacy, and any new trial would take time and capital the company may not have. TENX reported a GAAP net loss of about $16.7 million for the quarter ended September 30, 2026, and carries negative EPS (earnings per share). Securities class-action lawsuits alleging the company overstated TNX-103's prospects add legal overhang and potential expense. The wide analyst range — from $4 to $35 — reflects a real possibility that the surviving higher targets are optimistic relative to the data. Further dilution from a capital raise would also pressure the per-share value required to reach $9.60.

Technical Levels and Market Structure

Technically, the stock is deeply broken. Shares sit far below their 50-day and 200-day moving averages after the August collapse, and the price has continued to drift lower into the low-$1.20s, testing the post-trial lows near $1.31. The prior trading range above $13 is now a distant memory, and there is little nearby technical support structure. On the upside, any durable recovery would first need to reclaim the mid-single-digit zone where post-trial analyst targets cluster ($4 to $5), making that area a meaningful resistance zone before any move toward $9.60 could be contemplated.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though the actual horizons here vary by firm and are not uniformly disclosed. Investors should watch for updates on the strategic-alternatives process, any redesign or readout from the levosimendan program in PH-HFpEF subgroups, progress on the imatinib-based TNX-201 program, quarterly cash and burn updates, and any analyst target revisions. The December 28, 2026 lead-plaintiff deadline in the securities class actions is also a near-term event to track.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For a volatile micro-cap such as TENX, where news can move the stock sharply, automated signal monitoring can help traders stay current as conditions evolve.

Final Assessment

The question of whether TENX can reach $9.60 is best understood as a question about whether the company's remaining pipeline and strategic process can justify a valuation roughly seven times the current price. The central target is the mean of eight surviving analyst targets, but that mean conceals a range from $4 to $35 and omits two firms that withdrew targets altogether. The strongest supports are the severe-PH-HFpEF subgroup thesis, insider buying, and a strategic review; the principal obstacles are the failed pivotal trial, financing needs, and litigation. Because the stock has already fallen so far, even modestly positive news could drive large percentage moves — but a sustained re-rating toward $9.60 would require clinical or corporate catalysts that have not yet materialized. No outcome is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TENX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TENX
1D Price
Change %
TENX100%
-10.07%
SION - TENX
93%
Closely correlated
-4.88%
AVXL - TENX
47%
Loosely correlated
-11.39%
CORT - TENX
41%
Loosely correlated
-2.09%
HRTX - TENX
40%
Loosely correlated
-4.39%
MGNX - TENX
32%
Poorly correlated
-1.01%
More

Groups containing TENX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TENX
1D Price
Change %
TENX100%
-10.07%
TENX
(2 stocks)
96%
Closely correlated
-7.48%
Can Tenax Therapeutics (TENX) Stock Reach $9.60?